Encompass Health Corporation filings document the operating results, financing arrangements and governance matters of a public inpatient rehabilitation hospital company. Its Form 8-K reports furnish earnings releases, Regulation FD materials, same-store performance measures and non-GAAP metrics such as adjusted earnings per share, leverage ratio, Adjusted EBITDA and adjusted free cash flow.
Other filings record capital-structure and governance subjects, including the company's credit agreement, revolving credit facility, subsidiary guarantor arrangements, board appointments, committee assignments and director compensation practices. The definitive proxy statement addresses annual meeting proposals, executive compensation, pay-versus-performance disclosure, board structure and stockholder voting matters.
Encompass Health Corp EVP & Chief Financial Officer Douglas E. Coltharp reported tax-related share dispositions in Encompass Health Common Stock. On February 20, 2026, 674 shares were withheld at $106.55 per share, and on February 19, 2026, 16,708 shares were withheld at $107.15 per share.
According to the footnote, these shares were withheld or surrendered to pay tax withholding obligations tied to the vesting of restricted stock, rather than sold in open-market transactions. After these dispositions, Coltharp directly owned 84,971 shares, with additional indirect holdings reported through irrevocable trusts and a spouse.
Encompass Health Corp EVP and COO Patrick William Tuer reported two tax-related share dispositions tied to restricted stock vesting. On February 19, 2026, 3,193 shares of Encompass Health common stock were withheld at $107.15 per share to cover tax obligations. On February 20, 2026, an additional 405 shares were withheld at $106.55 per share for the same purpose. After these non-open-market transactions, Tuer directly owned 26,488 shares of Encompass Health common stock.
Encompass Health Corporation filed an amended report to update a recent Board change. The Board had unanimously approved the appointment of Cain A. Hayes as a director on January 30, 2026. The amendment notes that on February 19, 2026, the Board appointed Mr. Hayes to the Compensation and Human Capital Committee and the Compliance and Quality of Care Committee. This filing supplements an earlier report originally filed on February 2, 2026, by providing these committee assignments for the new director.
Encompass Health Corp Chief Medical Officer Elissa Joy Charbonneau reported stock awards in the company’s common stock. On February 18, 2026, she acquired 8,914 shares at $0.00 per share as an annual restricted stock award under the 2025 Omnibus Performance Incentive Plan. On February 19, 2026, she acquired an additional 1,884 shares of restricted stock at $0.00 per share upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. Following these grants, she directly owned a total of 22,756.061 shares of Encompass Health common stock.
Encompass Health Corp executive John Patrick Darby, EVP, General Counsel & Secretary, reported two stock awards. On February 18, 2026, he acquired 17,720 shares of common stock, and on February 19, 2026, he received 2,154 restricted shares. Following these grants, he directly holds 99,584 shares of Encompass Health common stock.
Encompass Health Corp EVP & Chief Financial Officer Douglas E. Coltharp reported stock awards in Encompass Health Common Stock. On February 18, 2026, he acquired 37,588 shares as an annual restricted stock award pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan. On February 19, 2026, he acquired an additional 4,430 restricted shares upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. After these grants, his directly held stake increased to 102,353 shares, and the filing also notes indirect holdings through irrevocable trusts and his spouse.
Encompass Health Corp reported stock awards to Chief Accounting Officer Andrew L. Price. He acquired 8,178 shares of Encompass Health common stock on February 18, 2026 and 1,560 shares on February 19, 2026, both at a stated price of $0.00 per share.
The 8,178-share issuance reflects restricted stock delivered after meeting performance criteria from a February 23, 2023 performance share unit award. The 1,560-share grant is an annual restricted stock award under the company’s 2025 Omnibus Performance Incentive Plan.
Encompass Health Corp reported that President and CEO Mark J. Tarr acquired company stock through equity awards, rather than open-market purchases. On February 19, 2026, he received 12,796 shares of Encompass Health common stock at $0.00 per share, increasing his direct holdings to 490,812 shares. This issuance of restricted stock resulted from meeting performance criteria under a performance share unit award granted on February 23, 2023.
On February 18, 2026, Tarr was also granted 100,946 shares of restricted stock at $0.00 per share, bringing his direct ownership to 478,016 shares immediately after that grant. This award was an annual restricted stock grant made under the corporation's 2025 Omnibus Performance Incentive Plan.
Encompass Health Corp senior vice president and treasurer Edmund Fay reported equity awards of company common stock. On February 18, 2026, he acquired 7,690 shares of restricted stock at $0.00 per share as a grant or award. On February 19, 2026, he acquired an additional 1,430 restricted shares at $0.00 per share.
The filing notes that 1,430 shares were issued upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. The 7,690-share transaction is described as an annual restricted stock award under the corporation's 2025 Omnibus Performance Incentive Plan. After these transactions, Fay directly owned over one hundred thousand Encompass Health common shares.
Encompass Health Corp executive Patrick William Tuer, EVP and Chief Operating Officer, reported acquiring company stock through equity awards. On February 18, 2026, he received 10,254 shares of Encompass Health common stock at a price of $0.00 per share as a grant or award, bringing his direct holdings to 26,296 shares.
On February 19, 2026, he received an additional 3,790 restricted shares at $0.00 per share, increasing his direct ownership to 30,086 shares. Footnotes state that one issuance reflects satisfaction of performance criteria from a February 23, 2023 performance share unit award, and the other is an annual restricted stock award under the 2025 Omnibus Performance Incentive Plan.